Indaptus Therapeutics Q1 2026 net loss $2.5M; cash burn concerns with only $1.5M left

Indaptus Therapeutics, Inc.

Q1 2026 net loss narrowed to $2.5M vs $4.5M YoY; loss per share $0.23 (post reverse split).
Cash and equivalents fell to $1.5M from $8.5M at Dec 2025; company needs to raise additional capital.
R&D expenses dropped 82% to $0.5M due to Phase 1 clinical cost decrease and headcount reductions.
Executive management transition underway; reassessing development priorities and Decoy platform.
Preferred stock conversion completed during Q1 2026; all Series AA and AAA shares converted to common.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.